Total Payments
$11,504
2024 Payments
$990.18
Companies
55
Transactions
854
Medicare Patients
19,144
Medicare Billing
$3.5M
Payment Breakdown by Category
Food & Beverage$11,301 (98.2%)
Education$202.50 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,301 | 848 | 98.2% |
| Education | $202.50 | 6 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,806 | 185 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $1,413 | 134 | $0 (2022) |
| Amgen Inc. | $753.13 | 54 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $681.09 | 39 | $0 (2024) |
| ABBVIE INC. | $627.28 | 43 | $0 (2024) |
| Alkermes, Inc. | $540.96 | 30 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $532.29 | 33 | $0 (2024) |
| Lilly USA, LLC | $518.37 | 41 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $341.29 | 22 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $319.68 | 22 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $990.18 | 57 | Amgen Inc. ($157.49) |
| 2023 | $1,646 | 89 | Amgen Inc. ($252.58) |
| 2022 | $1,471 | 97 | Amgen Inc. ($247.83) |
| 2021 | $1,777 | 122 | AbbVie Inc. ($375.27) |
| 2020 | $1,365 | 109 | Novo Nordisk Inc ($327.60) |
| 2019 | $2,016 | 177 | Sunovion Pharmaceuticals Inc. ($573.64) |
| 2018 | $1,187 | 117 | Sunovion Pharmaceuticals Inc. ($298.78) |
| 2017 | $1,051 | 86 | Daiichi Sankyo Inc. ($183.00) |
All Payment Transactions
854 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $8.09 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: CNS | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $18.86 | General |
| 12/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.57 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/05/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: UROLOGY | ||||||
| 10/30/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $5.90 | General |
| Category: Inflammation | ||||||
| 10/15/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: CNS | ||||||
| 10/07/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: UROLOGY | ||||||
| 09/24/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $10.55 | General |
| Category: Inflammation | ||||||
| 09/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Diabetes | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.95 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: PSYCHIATRY | ||||||
| 09/03/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: CNS | ||||||
| 08/14/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: CNS | ||||||
| 08/12/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Biological | ||||||
| 08/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: Inflammation | ||||||
| 08/06/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: CNS | ||||||
| 08/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.69 | General |
| Category: PSYCHIATRY | ||||||
| 07/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 4,471 | 60,962 | $2.2M | $1.1M |
| 2022 | 26 | 4,439 | 28,304 | $1.4M | $707,199 |
| 2021 | 57 | 4,407 | 13,459 | $1.7M | $778,498 |
| 2020 | 70 | 5,827 | 16,238 | $1.9M | $957,078 |
Total Patients
19,144
Total Services
118,963
Medicare Billing
$3.5M
Procedure Codes
180
All Medicare Procedures & Services
180 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | Office | 2023 | 1,598 | 48,610 | $874,980 | $571,524 | 65.3% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 115 | 343 | $229,741 | $91,101 | 39.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 323 | 956 | $232,461 | $78,753 | 33.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 213 | 1,027 | $140,370 | $60,016 | 42.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 279 | 372 | $141,613 | $47,689 | 33.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 402 | 991 | $75,671 | $43,475 | 57.5% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 21 | 4,081 | $114,105 | $42,953 | 37.6% |
| 96112 | Administration of developmental test, first hour | Office | 2023 | 116 | 346 | $86,625 | $33,050 | 38.2% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 113 | 137 | $63,050 | $26,794 | 42.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 201 | 417 | $71,232 | $22,306 | 31.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 185 | 240 | $48,114 | $20,144 | 41.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 294 | 575 | $40,051 | $19,839 | 49.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 119 | 136 | $18,551 | $8,107 | 43.7% |
| 90901 | Biofeedback training | Office | 2023 | 42 | 192 | $14,508 | $5,658 | 39.0% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 69 | 95 | $12,308 | $4,891 | 39.7% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 30 | 1,800 | $12,996 | $4,718 | 36.3% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 13 | 47 | $8,038 | $3,738 | 46.5% |
| 97129 | Therapy procedure for a range of mental processes, initial 15 minutes | Office | 2023 | 43 | 212 | $9,532 | $3,657 | 38.4% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 57 | 62 | $9,371 | $3,501 | 37.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 50 | 70 | $6,513 | $2,436 | 37.4% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 14 | 14 | $6,621 | $1,743 | 26.3% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 11 | 16 | $3,754 | $1,360 | 36.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,108 | $1,232 | 30.0% |
| 93050 | Analysis of central arterial pressure with review by physician | Office | 2023 | 92 | 99 | $2,936 | $1,127 | 38.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 28 | 34 | $2,598 | $961.95 | 37.0% |
About Dr. Abdullah Arshad, MD
Dr. Abdullah Arshad, MD is a Internal Medicine healthcare provider based in Hayti, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477660637.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abdullah Arshad, MD has received a total of $11,504 in payments from pharmaceutical and medical device companies, with $990.18 received in 2024. These payments were reported across 854 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($11,301).
As a Medicare-enrolled provider, Arshad has provided services to 19,144 Medicare beneficiaries, totaling 118,963 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 180 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Emergency Medicine, Internal Medicine
- Location Hayti, MO
- Active Since 08/24/2006
- Last Updated 10/03/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1477660637
Products in Payments
- Ozempic (Drug) $996.17
- LATUDA (Drug) $980.56
- REXULTI (Drug) $733.76
- Otezla (Drug) $616.05
- VRAYLAR (Drug) $574.68
- ARISTADA (Drug) $517.17
- GEMTESA (Drug) $424.40
- FARXIGA (Drug) $255.03
- Tresiba (Drug) $255.02
- EMGALITY (Drug) $247.75
- SOLIQUA (Drug) $227.31
- Victoza (Drug) $220.46
- Rybelsus (Drug) $214.98
- Movantik (Drug) $195.48
- CHANTIX (Drug) $184.17
- XIFAXAN (Drug) $174.84
- TRADJENTA (Drug) $173.73
- UBRELVY (Drug) $172.03
- JARDIANCE (Drug) $157.17
- TRULICITY (Drug) $153.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.